Valsartan NDMA Lawsuit 2026: the $15.26M Settlement You May Have Missed & Who Can Still File

If you bought valsartan, losartan, or irbesartan during the recall years, the consumer class-action window has closed: three settlements totaling $15.26 million shut their claim deadline on June 2, 2026, with final approval on June 30. The larger personal-injury litigation, MDL 2875, is also largely resolved.

Key facts

  • $15.26 million total: Hetero valsartan ($11.37M), Aurobindo irbesartan ($2M), and Vivimed losartan ($1.9M) — three class-action settlements for contaminated blood-pressure drugs.
  • June 2, 2026: the claim-filing deadline. The final approval hearing was held June 30, 2026. The window is now closed and cannot be extended.
  • FDA safe limit: 0.096 micrograms of NDMA per day; recalled valsartan pills carried 3 to 177 times that level — up to 20 micrograms, over 200 times the safe amount.
  • Recalls began in 2018, but contaminated products had been sold since as early as 2012 — exposing long-term users for years before anyone knew.
  • October 2026 status: the federal personal-injury litigation (MDL 2875) is largely resolved, and firms are no longer investigating new cases.

What Went Wrong: NDMA in a Blood-Pressure Pill

Valsartan is an ARB — an angiotensin II receptor blocker, a class of drugs that relaxes blood vessels and is prescribed to millions of people for high blood pressure and heart failure. The trouble was not the molecule itself but how some generic versions were manufactured. In 2018, the U.S. Food and Drug Administration began announcing recalls after testing found nitrosamine impurities — NDMA (N-nitrosodimethylamine, an industrial chemical classified as a probable human carcinogen), plus related impurities NDEA and NMBA — in valsartan made with active ingredients from manufacturers including Zhejiang Huahai, Hetero, Aurobindo, and Vivimed. The contamination had apparently been occurring since as early as 2012. The figures turned a defect into a national recall: the FDA considers 0.096 micrograms of NDMA per day an acceptable intake, yet recalled tablets contained 3 to 177 times that level — some testing showed up to 20 micrograms per pill, more than 200 times the safe amount.

The $15.26 Million Settlement, Explained

The consumer side of the litigation resolved as three class-action settlements totaling $15.26 million: Hetero's valsartan settlement at $11.37 million, Aurobindo's irbesartan settlement at $2 million, and Vivimed's losartan settlement at $1.9 million. These were economic-loss cases — reimbursement for the money consumers spent on drugs that were allegedly not what they claimed to be — rather than personal-injury awards. The defendants denied that the impurity levels were harmful or carcinogenic. Pfizer's $44 million Chantix settlement followed a similar consumer-class-action path to final approval this year.

The Deadline You Missed: June 2, 2026

The claim-filing deadline for all three settlements was June 2, 2026, and the final approval hearing took place on June 30, 2026. That window is now permanently closed — class-action deadlines cannot be extended or reopened for late filers. Depo-Provera's settlement deadline is another current example of a claim window with a hard close date.

The Personal-Injury Side: MDL 2875

Parallel to the consumer class actions ran the personal-injury litigation: In re Valsartan, Losartan, and Irbesartan Products Liability Litigation, MDL No. 19-2875 — a multidistrict litigation, in which one federal judge handles pretrial proceedings for many similar lawsuits, established in the District of New Jersey in February 2019. By October 2019, more than 100 lawsuits were pending. Plaintiffs alleged the contaminated drugs contributed to cancer diagnoses, seeking compensation for medical expenses and injuries. The litigation never reached a plaintiff-friendly resolution: in 2025, federal judges excluded key causation experts under the Daubert and amended Rule 702 standards in bellwether proceedings — bellwethers being test trials whose outcomes help both sides value the remaining cases. By October 2026, legal monitors report the litigation is largely resolved and firms are no longer investigating new valsartan cases. Compensation varies widely by case, and most settlements in pharmaceutical litigation are confidential.

Which Cancers Were Linked to the Contamination

The cancers named in valsartan lawsuits included colorectal, intestinal (including small intestine), stomach and gastric, liver, esophageal, prostate, bladder, and lung cancers, plus blood cancers such as non-Hodgkin's lymphoma, multiple myeloma, and leukemia. The science cited by plaintiffs included a Swedish study of 61,433 women linking NDMA-contaminated valsartan to a higher risk of gastric cancer, and a French study of 986,126 users suggesting a higher probability of liver cancer.

What to Do If You Missed the Deadline

First, do not stop taking your blood-pressure medication — an untreated hypertension risk is immediate and certain, while the contamination affected specific recalled batches years ago. Check the FDA's searchable recall list to confirm whether your past prescription came from an affected manufacturer; most pharmacies switched to unaffected suppliers long ago. Keep your pharmacy records and any cancer-diagnosis documentation in one place, because pharmaceutical contamination class actions recur — new cases over different drugs are filed regularly, and a missed deadline in one case does not bar you from future ones. An attorney can give you an honest assessment of whether any individual claim remains viable, though the large-scale channels are closed. For accessible explainers on drug and insurance topics, the Problem Solved YouTube channel publishes plain-English guides. And our valsartan lawsuit guide covers the filing mechanics for reference.

Who Benefits From This — and Who Does Not

This article is for readers who bought valsartan, losartan, or irbesartan during the recall years and want to know whether anything is still open for them — and it is equally clear about where the window has closed.

Who benefits:

  • Buyers of the affected generics: three class-action settlements totaled $15.26 million — Hetero valsartan at $11.37 million, Aurobindo irbesartan at $2 million, and Vivimed losartan at $1.9 million — and the claim deadline was June 2, 2026, with final approval on June 30, 2026. How to use this article: check your purchase records against the three groups, and read the section on what to do if you missed the deadline.
  • People with a personal injury linked to the contamination: the larger litigation, MDL 2875, is explained separately from the consumer class action. How to use this article: place your case on the personal-injury side rather than the closed consumer window if you link a cancer diagnosis to the contamination.
  • People still taking a blood-pressure medication: the article explains why stopping on your own would be wrong, and that the FDA maintains a searchable list of every recalled product. How to use this article: talk to your doctor instead of ending the medication yourself.

Who does not benefit:

  • People who never bought the affected generics: there is no claim in this settlement for them — the settlements covered only buyers of the named products during the recall years.
  • People waiting for a new claim window: the window for these three settlements cannot be extended or reopened, as the article states.
  • People expecting a fixed payout amount: individual class members' shares depended on what they purchased and how many claims were filed — no standard amount is promised in the article.

Read also: Oxbryta Lawsuit 2026: Pfizer Withdrew the Sickle Cell Drug — Who Can Still File & What the June 2027 Trial Means.

Frequently Asked Questions

Can I still file a claim for the valsartan settlement in 2026?

No. The claim deadline for the three class-action settlements was June 2, 2026, and the final approval hearing took place on June 30, 2026. The window cannot be extended or reopened for this settlement.

How much was the valsartan settlement?

Three class-action settlements totaled $15.26 million: Hetero valsartan at $11.37 million, Aurobindo irbesartan at $2 million, and Vivimed losartan at $1.9 million. Individual class members' shares depended on what they purchased and how many claims were filed.

What was wrong with the blood-pressure drugs?

Certain batches of generic valsartan, losartan, and irbesartan contained nitrosamine impurities — NDMA, NDEA, and NMBA — introduced during manufacturing. These chemicals are classified as probable human carcinogens. The manufacturers deny that the levels found were harmful.

Should I stop taking valsartan?

Do not stop taking any prescribed blood-pressure medication on your own. The FDA maintains a searchable list of every recalled product, and most prescriptions were switched to unaffected manufacturers years ago. Talk to your doctor about any concern.

Who benefits most from this Valsartan settlement article?

Buyers of generic valsartan, losartan, or irbesartan during the recall years, and readers who want to tell the closed consumer class-action window apart from the personal-injury side, MDL 2875.

How do I proceed now if I missed the deadline?

Check whether you were among the affected buyers, read the section on what to do if you missed the deadline, do not stop any prescribed blood-pressure medication on your own, and raise any personal-injury question with your doctor and — where applicable — a qualified attorney.

This article provides general information about a litigation and is not legal advice. If you need legal advice about a specific situation, consult a licensed attorney. Do not stop taking any prescribed medication without talking to your doctor.

Watch on YouTube

Problem Solved on YouTube